Humacyte (HUMA) Competitors $1.69 +0.05 (+2.74%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$1.68 -0.01 (-0.89%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HUMA vs. TRVI, COLL, PGEN, RAPP, SYRE, IMNM, PHAR, IMTX, SPRY, and VALNShould you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Trevi Therapeutics (TRVI), Collegium Pharmaceutical (COLL), Precigen (PGEN), Rapport Therapeutics (RAPP), Spyre Therapeutics (SYRE), Immunome (IMNM), Pharming Group (PHAR), Immatics (IMTX), ARS Pharmaceuticals (SPRY), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry. Humacyte vs. Its Competitors Trevi Therapeutics Collegium Pharmaceutical Precigen Rapport Therapeutics Spyre Therapeutics Immunome Pharming Group Immatics ARS Pharmaceuticals Valneva Humacyte (NASDAQ:HUMA) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability. Does the media favor HUMA or TRVI? In the previous week, Humacyte had 10 more articles in the media than Trevi Therapeutics. MarketBeat recorded 17 mentions for Humacyte and 7 mentions for Trevi Therapeutics. Humacyte's average media sentiment score of 0.34 beat Trevi Therapeutics' score of 0.20 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 7 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, HUMA or TRVI? Humacyte has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Which has stronger valuation and earnings, HUMA or TRVI? Trevi Therapeutics has lower revenue, but higher earnings than Humacyte. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$818K327.20-$148.70M-$0.45-3.76Trevi TherapeuticsN/AN/A-$47.91M-$0.42-23.38 Do institutionals & insiders have more ownership in HUMA or TRVI? 44.7% of Humacyte shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 5.1% of Humacyte shares are held by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate HUMA or TRVI? Humacyte presently has a consensus price target of $9.29, indicating a potential upside of 449.45%. Trevi Therapeutics has a consensus price target of $21.75, indicating a potential upside of 121.49%. Given Humacyte's higher possible upside, equities analysts clearly believe Humacyte is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Is HUMA or TRVI more profitable? Humacyte's return on equity of 0.00% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A N/A -78.26% Trevi Therapeutics N/A -41.44%-38.21% SummaryTrevi Therapeutics beats Humacyte on 8 of the 15 factors compared between the two stocks. Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMA vs. The Competition Export to ExcelMetricHumacyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$260.52M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-3.7621.5785.5627.61Price / Sales327.20271.42535.65201.12Price / CashN/A47.1237.9261.55Price / Book-4.1210.1413.036.76Net Income-$148.70M-$52.31M$3.30B$275.88M7 Day Performance-5.59%5.14%4.35%2.81%1 Month Performance12.67%14.68%9.50%9.24%1 Year Performance-68.62%30.98%85.16%35.42% Humacyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAHumacyte2.8328 of 5 stars$1.69+2.7%$9.29+449.5%-69.5%$260.52M$818K-3.76150Trending NewsAnalyst ForecastOptions VolumeHigh Trading VolumeTRVITrevi Therapeutics2.4928 of 5 stars$8.95+2.1%$21.75+143.0%+211.7%$1.09BN/A-21.3120Analyst ForecastCOLLCollegium Pharmaceutical4.1521 of 5 stars$34.57+0.5%$42.33+22.5%-12.9%$1.09B$631.45M33.24210News CoveragePositive NewsAnalyst ForecastPGENPrecigen4.4302 of 5 stars$3.63+3.4%$8.25+127.3%+276.3%$1.08B$3.92M-8.64190Analyst ForecastGap UpRAPPRapport Therapeutics3.0183 of 5 stars$27.97+5.2%$35.33+26.3%+37.3%$1.02BN/A-11.19N/AAnalyst ForecastGap UpHigh Trading VolumeSYRESpyre Therapeutics3.2735 of 5 stars$16.36+0.7%$54.29+231.8%-36.6%$988.14M$890K-4.8173Analyst DowngradeIMNMImmunome1.4134 of 5 stars$11.34-2.2%$23.20+104.6%+8.6%$987.03M$9.04M-3.6840Analyst ForecastGap UpPHARPharming Group2.3119 of 5 stars$14.29+3.6%$30.00+109.9%+69.5%$979.01M$297.20M-109.92280Analyst ForecastShort Interest ↑High Trading VolumeIMTXImmatics2.4272 of 5 stars$7.91+2.7%$15.00+89.6%-5.5%$961.46M$168.65M-12.17260Analyst ForecastSPRYARS Pharmaceuticals2.9139 of 5 stars$9.72-0.8%$33.17+241.2%-20.0%$960.63M$89.15M-19.8490Analyst ForecastVALNValneva2.4529 of 5 stars$10.95+12.8%$15.00+37.0%+88.9%$940.90M$196.33M-11.17700Analyst Forecast Related Companies and Tools Related Companies TRVI Competitors COLL Competitors PGEN Competitors RAPP Competitors SYRE Competitors IMNM Competitors PHAR Competitors IMTX Competitors SPRY Competitors VALN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HUMA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
